{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:56:27Z","timestamp":1780995387337,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myocarditis in patients treated with immune checkpoint inhibitors has previously been reported to be rare, though it has most likely been underreported owing to misdiagnosis in the absence of overt clinical presentation. Early detection and characterization of this potentially life-threatening immune-related adverse event is of major importance. Herein we report a case of early-onset myocarditis in an asymptomatic patient treated with dual checkpoint inhibition for metastatic cholangiocarcinoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 69-year-old male Caucasian patient with metastatic cholangiocarcinoma presented with mild epigastric pain and troponinemia prior to the third dose of dual checkpoint inhibition (ipilimumab 1\u00a0mg\/kg body weight and nivolumab 3\u00a0mg\/kg body weight). Initial workup showed no significant abnormalities (physical\/neurological examination, electrocardiogram, 72-hour Holter monitoring, and a transthoracic echocardiogram). However, cardiac magnetic resonance imaging revealed a zone of contrast enhancement in the inferior segment of the left ventricular wall indicating a recent episode of myocarditis. Despite steroid initiation (0.5\u00a0mg\/kg oral prednisolone per day), troponin levels kept increasing, in the absence of coronary disease, for which steroids were increased to 1.5\u00a0mg\/kg\/day. Fluorodeoxyglucose positron emission tomography\/computed tomography, 28\u00a0days after detecting elevated troponin levels, depicted multiple zones of active myocardial inflammation (basal septal, mid-anterior, and apical inferior). The patient is currently stable, and troponinemia is slowly decreasing while steroids are steadily being tapered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>As the number of cancers treated with immune checkpoint inhibitors is expanding, the incidence of immune checkpoint inhibitor-induced myocarditis is likely to increase. Moreover, the emerging combination of immune checkpoint inhibitors with non-immune checkpoint inhibitor therapies with potential synergistic cardiotoxic side effects (for example, tyrosine kinase inhibitors) will further complicate the diagnosis of immune-related cardiotoxicity. This case highlights the urgent need for predictive biomarkers to stratify patients at risk and to develop a standardized and multidisciplinary management approach for early diagnosis and treatment of this severe immune-related adverse event.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03487-4","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T23:05:07Z","timestamp":1657753507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Danielle","family":"Delombaerde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Vervloet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Berwouts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Gremonprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieselot","family":"Croes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Vulsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"3487_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2: e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535.","journal-title":"JAMA Netw Open"},{"key":"3487_CR2","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et\u00a0al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","journal-title":"J Clin Oncol"},{"key":"3487_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et\u00a0al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214.","journal-title":"N Engl J Med"},{"key":"3487_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et\u00a0al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"key":"3487_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et\u00a0al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854\u201368. https:\/\/doi.org\/10.1093\/cvr\/cvz026.","journal-title":"Cardiovasc Res"},{"key":"3487_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.079","author":"S Ball","year":"2019","unstructured":"Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Gopal C, Ghosh C, et\u00a0al. The present and future JACC review topic of the week cardiovascular toxicities of immune checkpoint inhibitors. JACC Rev Topic Week. 2019. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.079.","journal-title":"JACC Rev Topic Week"},{"key":"3487_CR7","unstructured":"Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis and ACS\u2014American College of Cardiology n.d. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/10\/30\/15\/06\/diagnosis-and-treatment-of-immune-checkpoint-inhibitor-associated-myocarditis-and-acs accessed 18 Feb 2021."},{"key":"3487_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-00930-x","volume":"22","author":"V Bracun","year":"2020","unstructured":"Bracun V, Aboumsallem JP, van der Meer P, de Boer RA. Cardiac biomarkers in patients with cancer: considerations, clinical implications, and future avenues. Curr Oncol Rep. 2020;22:1\u201311. https:\/\/doi.org\/10.1007\/s11912-020-00930-x.","journal-title":"Curr Oncol Rep"},{"key":"3487_CR9","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017."},{"key":"3487_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","volume":"101","author":"N Pavo","year":"2015","unstructured":"Pavo N, Raderer M, H\u00fclsmann M, Neuhold S, Adlbrecht C, Strunk G, et\u00a0al. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 2015;101:1874\u201380. https:\/\/doi.org\/10.1136\/heartjnl-2015-307848.","journal-title":"Heart"},{"key":"3487_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178607","author":"S Bando","year":"2017","unstructured":"Bando S, Soeki T, Matsuura T, Tobiume T, Ise T, Kusunose K, et\u00a0al. Plasma brain natriuretic peptide levels are elevated in patients with cancer. PLoS ONE. 2017. https:\/\/doi.org\/10.1371\/journal.pone.0178607.","journal-title":"PLoS ONE"},{"key":"3487_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0140-6736(03)13976-1","volume":"362","author":"JA De Lemos","year":"2003","unstructured":"De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(03)13976-1.","journal-title":"Lancet"},{"key":"3487_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.11.012","author":"L Zhang","year":"2021","unstructured":"Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC CardioOncol. 2021. https:\/\/doi.org\/10.1016\/j.jaccao.2020.11.012.","journal-title":"JACC CardioOncol"},{"key":"3487_CR14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et\u00a0al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.007.","journal-title":"J Am Coll Cardiol"},{"key":"3487_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1158-0","author":"W Chen","year":"2019","unstructured":"Chen W, Jeudy J. Assessment of myocarditis: cardiac MR, PET\/CT, or PET\/MR? Curr Cardiol Rep. 2019. https:\/\/doi.org\/10.1007\/s11886-019-1158-0.","journal-title":"Curr Cardiol Rep"},{"key":"3487_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","volume":"59","author":"I Kindermann","year":"2012","unstructured":"Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et\u00a0al. Update on myocarditis. J Am Coll Cardiol. 2012;59:779\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.074.","journal-title":"J Am Coll Cardiol"},{"key":"3487_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0735-1097(94)90742-0","volume":"23","author":"PJ Keeling","year":"1994","unstructured":"Keeling PJ, Lukaszyk A, Poloniecki J, Caforio ALP, Davies MJ, Booth JC, et\u00a0al. A prospective case\u2013control study of antibodies to Coxsackie B virus in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;23:593\u20138. https:\/\/doi.org\/10.1016\/0735-1097(94)90742-0.","journal-title":"J Am Coll Cardiol"},{"key":"3487_CR18","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(18)30457-1.","journal-title":"Lancet Oncol"},{"key":"3487_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.016","author":"T Powles","year":"2021","unstructured":"Powles T, Guidelines CE. Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer. Ann Oncol. 2021. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.016.","journal-title":"Ann Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03487-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T23:06:04Z","timestamp":1657753564000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03487-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3487"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03487-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the fundamental principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}